Original Text: |
    The effects of paxalisib (GDC-0084) on the developing human fetus are unknown and radiotherapy has known teratogenic effects so women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 7 months after completion of trastuzumab administration per recommendations from the trastuzumab package insert
Disease/Condition: none
Procedure: Radiotherapy
Drug: none
Biomarker: none
Computable Rule: |
    "Paxalisib (GDC-0084)" AND ("Radiotherapy") AND ("Women of child-bearing potential" OR "Men") AND ("Adequate contraception")
